SDC1 and Miyoshi myopathy: Considering that a significant percentage of patients with standard/intermediate risk can harbor pathogenic/potentially pathogenic mutations, the combination of plasma cell separation and sequencing the CD138-positive fraction is a reliable option to detect somatic mutation at diagnosis in MM.